Rapamune

Quick links to important sections

Rapamune

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rapamune

Property Description
Active Ingredient Sirolimus (INN)
Form Oral tablet, Oral solution
Pharmacological Class Immunosuppressive agent
Common Use Maintenance immunosuppression
Origin Semi-synthetic macrolide (from Streptomyces hygroscopicus)

What is Rapamune and its Pharmacological Identity?

Rapamune is a prescription-only medication whose active ingredient is Sirolimus, a potent compound used to modulate the body's immune response. This medicine belongs to the pharmacological class of immunosuppressive agents and is specifically identified as a mammalian Target of Rapamycin (mTOR) inhibitor. The ingredient Sirolimus is a macrolide compound, unique because it is a semi-synthetic derivative originally isolated from the bacterium Streptomyces hygroscopicus, which explains its historical name, rapamycin. Sirolimus is a signal transduction inhibitor that prevents T-lymphocyte activation and proliferation. This confirms that the medicine works by blocking specific signals needed for key immune cells to multiply. This mechanism is clinically recognized for its selective effect on the cell cycle, which supports its utility in long-term immune management.

Composition, Forms, and General Therapeutic Purpose

Rapamune is formulated as a single active ingredient product containing only Sirolimus, and is available for oral administration in two principal forms: the film-coated tablet and the oral solution. Its primary role is in maintenance immunosuppression. Sirolimus is a drug that limits the body's rejection of transplanted organs. This means the medication is used long-term to help the body accept foreign tissue, such as a kidney or liver transplant. A key distinguishing feature of Rapamune is its oral solution formulation, which is often preferred in clinical settings for its capacity to allow for precise dose adjustments, supporting individual patient needs. By acting as a targeted signal blocker that arrests the rapid reproduction of key immune cells, Rapamune's overarching goal is to reduce the power of the body's defensive response and supports the long-term acceptance of the new tissue.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Rapamune?

The safety profile of Rapamune (Sirolimus) is defined by its role as an immunosuppressive agent, as documented in official government regulatory information, which outlines adverse reactions by frequency and potential seriousness.

Serious Documented Safety Concerns

Official labeling includes a warning regarding the increased susceptibility to infection and the possible development of lymphoma and other malignancies. Rapamune is not recommended for use in liver or lung transplant recipients, a restriction documented due to associations with excess mortality, graft loss, and severe vascular complications.

Serious reactions documented in official sources also include Thrombotic Microangiopathy (TMA) and conditions such as Interstitial Lung Disease or Non-Infectious Pneumonitis. Additionally, hypersensitivity events, including anaphylaxis and angioedema, have been reported.

General Systemic Adverse Reactions

Adverse reactions are classified by frequency as observed in clinical studies for renal transplant prophylaxis. Very Common events, occurring in ten percent or more of patients, encompass several systemic changes across multiple organ classes:

  • Metabolic and Vascular: Hypercholesterolemia (high cholesterol), Hypertriglyceridemia, Hypertension, and Peripheral edema (swelling).
  • Gastrointestinal: Abdominal pain and Diarrhea.
  • Renal and Hematological: Increase in creatinine levels and Anemia (low red blood cell count).

Safety Considerations in Specific Contexts

The medicine's safety profile includes specific constraints. The clearance of Sirolimus may be reduced in patients with impaired hepatic function; therefore, an official dose reduction is recommended in cases of severe hepatic impairment. A long-term safety pattern noted in regulatory documentation is the increased risk of decline in renal function when used with certain other immunosuppressants. Use is officially contraindicated in patients with known hypersensitivity to the active ingredient or excipients.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information states that experience with Rapamune (Sirolimus) overdose is limited. Documented presentations have ranged from instances where the individual remained asymptomatic to specific reports involving a severe, but transient atrial fibrillation. In general, the adverse effects expected during an overdose are consistent with those listed in the official adverse reactions section of the prescribing information.

Emergency Action Requirements

Immediate medical attention must be sought for any suspected overdose. The official guidance requires contacting emergency services immediately if the affected individual displays specific, life-threatening symptoms, including having a seizure, trouble breathing, collapsing, or being unable to be awakened. In all cases of overdose, contact with the poison control helpline is mandated.

Management and Procedural Constraints

The management of a Sirolimus overdose is focused on symptomatic and supportive treatment. This approach is required because official prescribing information specifies that Rapamune is not dialyzable to any significant extent. This constraint is due to the drug’s high level of protein and erythrocyte binding and its poor aqueous solubility. Hospital monitoring and supportive care are essential when severe symptoms dictate a call to emergency services.

Therapeutic Uses of Rapamune

What Rapamune Treats: Main Uses and Benefits

The primary therapeutic benefit of Rapamune (Sirolimus) is commonly used to help with the chronic management of critical conditions by addressing the underlying conditions, generally focusing on assisting with organ function and systemic balance.

The medication is explicitly applied across two core therapeutic domains: prophylaxis against kidney transplant rejection and the treatment of Lymphangioleiomyomatosis (LAM).

Rapamune supports the patient during difficult episodes by easing the burden of chronic immune attack following transplantation. It plays a role in managing the potential for acute rejection symptoms, such as fever, pain, and loss of kidney function, which assists with maintaining functional stability over time. It is applied when appropriate for adult and adolescent renal transplant recipients. For patients with LAM, it may assist with managing the decline in lung function, thereby helping to reduce chronic shortness of breath and fatigue. This use contributes to easing the overall symptom load for patients managing this complex, chronic condition and may be part of symptomatic management for associated systemic manifestations, such as renal angiomyolipomas (kidney tumors).


Quick Fact: Supportive Relief for Transplant and Rare Disease

Rapamune is commonly used to help with preventing symptoms that interfere with daily functioning after a kidney transplant. It also supports general well-being during symptomatic phases of Lymphangioleiomyomatosis, helping to manage symptoms linked to organ-specific functional stress.

Eligibility and Restrictions for Use

Rapamune (sirolimus) eligibility is strictly defined by regulatory documents, primarily for the prophylaxis of organ rejection in renal transplant patients aged 13 years and older.


Populations for Whom Use is Restricted or Contraindicated

Classification Population/Condition
Contraindicated Patients with a known hypersensitivity to sirolimus or any component of the formulation.
Use Not Recommended Liver Transplant Patients: Use is associated with excess mortality, graft loss, and hepatic artery thrombosis.
Use Not Recommended Lung Transplant Patients: Safety and efficacy are not established, and there are reports of bronchial anastomotic complications.
Restricted Use Severe Hepatic Impairment: Maintenance dose requires reduction (e.g., by approximately one-half) due to reduced clearance; requires close monitoring.
Use Not Established Pediatric Patients under 13 years old for organ rejection prophylaxis.
Conditional Use Females of Reproductive Potential must use effective contraception during and for 12 weeks after therapy due to potential fetal risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Rapamune (Sirolimus) is primarily governed by pharmacokinetic interactions because the medicine is a substrate of the metabolic enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp).

Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Regulatory Statement
PK Increase in Exposure Strong CYP3A4/P-gp Inhibitors (e.g., Ketoconazole, Verapamil, Cyclosporine) Substantially increase Sirolimus concentrations by reducing its clearance.
PK Decrease in Exposure Strong CYP3A4/P-gp Inducers (e.g., Rifampin, Phenytoin, St. John's wort) Substantially decrease Sirolimus concentrations by accelerating its metabolism.
Pharmacodynamic Nephrotoxic Agents (e.g., Calcineurin Inhibitors) Co-administration may carry a risk of additive nephrotoxicity.

Formal Constraints and Prohibitions

Co-administration with live vaccines is formally contraindicated due to the immunosuppressive properties of Sirolimus. Consumption of grapefruit or grapefruit juice is prohibited as it is documented to increase Sirolimus blood concentration. A mandatory separation rule requires that Sirolimus must be administered 4 hours after the dose of Cyclosporine to mitigate increased exposure. The severity of pharmacokinetic interactions is also documented as heightened in patients with impaired hepatic function due to reduced Sirolimus clearance.

All statements reflect regulatory information regarding interaction patterns and constraints.

Mechanism of Action

Targeting the Cellular Master Switch (mTORC1)

Rapamune's mechanism begins at the molecular level with the binding of Sirolimus to the intracellular protein FKBP-12. This complex then acts as an allosteric inhibitor of mTORC1 (mammalian Target of Rapamycin Complex 1), a central enzyme complex that functions as a cellular master switch for growth and division. By targeting this essential kinase, the drug engages a mechanism that regulates overactive cellular proliferation signals.

Halting T-Cell Multiplication and Proliferation

The inhibition of mTORC1 kinase activity directly blocks the signal transduction cascade initiated by growth factors like Interleukin-2 (IL-2). This critical blockage prevents key immune cells, primarily T-lymphocytes, from synthesizing the proteins needed for division, effectively imposing an arrest in the G1 phase of their cell cycle. This action suppresses the multiplication (clonal expansion) of activated immune cells, resulting in a selective reduction of T-lymphocyte activity.

Limiting Systemic Cellular Growth Signals

Beyond its effect on T-cells, the mechanism influences systems where the mTORC1 pathway regulates cell growth, as it is essential for signals in other tissues, including vascular smooth muscle cells. By modifying the growth and proliferation signals across various cell types, the mechanism influences the regulation of cell growth and migration, impacting signaling dynamics within pathways throughout the body.

Dosage and Administration Information

Rapamune (sirolimus) is administered orally once daily and requires careful, consistent timing to ensure stable medication levels in the blood.

Administration Method and Timing

Procedural Step Official Instruction
Route & Frequency Oral, once daily.
Consistency Must be taken consistently with or without food.
Cyclosporine Separation When co-administered with cyclosporine, take Rapamune 4 hours after the cyclosporine dose.
Food Restriction Avoid consumption of grapefruit or grapefruit juice.
Missed Dose Take the missed dose as soon as remembered, but do not take a double dose to make up for a forgotten one.

Preparation Guidelines

Formulation Preparation Instruction
Tablets Swallow whole. Do not crush, chew, or split.
Oral Solution Mix the exact dose in a glass or plastic cup containing at least 60 mL (2 oz) of water or orange juice only. Stir vigorously for one minute and drink immediately. Rinse the cup with at least 120 mL (4 oz) of water or orange juice, stir, and drink the rinse solution.

Dosing Guidance

The dosage is highly individualized and is determined by a physician based on therapeutic drug monitoring (TDM) of sirolimus whole blood trough concentrations. The goal is to maintain concentrations within specific target ranges. For kidney transplant prophylaxis, initial loading and maintenance doses are prescribed, with adjustments made to maintain the target therapeutic level, especially if co-administered drugs are discontinued or if liver function is impaired. Dose adjustments should not be made more frequently than every 7 to 14 days.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Rapamune (Sirolimus)

This overview describes the types of research studies that have been conducted with Rapamune (Sirolimus), focusing on what was studied for and what the findings reported, without providing personal medical advice or claims of certainty.


Evidence for Use in Management of Organ Rejection

This section summarizes the design and scope of Randomized Controlled Trials (RCTs) and long-term observational studies that examined its use in the management of organ rejection, comparing initial use with combination regimens and later conversion strategies.

Short-Term Trials and Initial Combination Use

In the early period following a kidney transplant, researchers conducted short-term RCTs to explore its potential role in the management of immune response. These studies monitored the occurrence of key clinical events, primarily examining the rate of biopsy-confirmed acute rejection and graft loss over periods typically lasting six months to one year. Initial trials research examined whether adding Sirolimus to certain standard immunosuppressive combinations was associated with differences in the reported measurements of acute rejection in the observed populations. Studies on maintenance therapy years after transplantation explored switching patients from a calcineurin inhibitor (CNI) to Sirolimus, monitoring functional outcomes related to the transplanted kidney, such as the Glomerular Filtration Rate (GFR).

Evidence for Use in Treating Lymphangioleiomyomatosis (LAM)

This section will outline the structure of the pivotal Phase III RCT and subsequent longitudinal studies, describing how researchers designed the trials to measure changes in lung function and other LAM-related systemic manifestations.

The evidence base for this indication includes the MILES (Multicenter International LAM Efficacy of Sirolimus) trial. This trial examined adult women with LAM who had outcomes describing episodic or acute changes in their lungs. The primary focus of the research was evaluated in monitoring the rate of decline in lung function, specifically the slope of the FEV₁ measurement, over a defined time interval. Findings described patterns observed in the studies where the rate of decline measurements differed between the Sirolimus group and the placebo group. Research also examined outcomes related to systemic manifestations, such as the volume of renal angiomyolipomas.

What Research Gaps and Uncertainty Remain

This final section will synthesize the major limitations and areas of ongoing research, clarifying which long-term or specific population outcomes are not yet well-characterized according to regulatory and scientific literature.

For transplant recipients, there is limited information for long-term outcomes beyond three to five years, making it difficult to understand patient-reported outcomes related to long-term graft function. For LAM, a key uncertainty is that long-term effects are not fully established concerning the sustained follow-up beyond the studied time intervals. Furthermore, data for certain groups remain insufficient across both indications, such as outcomes in patients with high immunologic risk or those with complex pre-existing or concurrent conditions.

Frequently Asked Questions (FAQ)

Common questions about Rapamune (FAQ)

Q: Is Rapamune the same compound as Rapamycin?

The active ingredient in Rapamune is Sirolimus. Sirolimus is chemically the same compound as Rapamycin, which was the original name given to the substance when it was first discovered. Official drug information recognizes Sirolimus as the formal generic name for this compound.


Q: Why is Rapamune sometimes called Rapamycin?

Rapamycin was the name originally given to the compound Sirolimus when it was first discovered. The compound was isolated from a bacterium found on Rapa Nui (Easter Island). Sirolimus is the internationally recognized official generic name (INN), but the historical name Rapamycin is still sometimes used.


Q: Why does Rapamune often cause mouth sores or canker sores?

Mouth sores, also known as stomatitis or aphthous ulcers, are documented as an adverse reaction associated with Rapamune. Regulatory documents report this as a common adverse reaction observed in clinical studies.


Q: How does Rapamune impact the body's natural wound healing process?

Official regulatory documents list the impairment of wound healing as a safety precaution. Regulatory warnings indicate that the medication may be associated with impaired wound healing.


Q: What does it mean if the Rapamune oral solution becomes hazy in the refrigerator?

According to patient instructions included with the official labeling, if the oral solution appears cloudy or hazy after being refrigerated, this is generally reversible. The product information states that haziness can be addressed by allowing the bottle to reach room temperature and then gently shaking it until the solution clears.


Q: Does Rapamune interact with alcohol consumption?

Regulatory documents do not list a direct interaction between Rapamune and alcohol. However, healthcare providers often advise caution, as alcohol consumption could potentially exacerbate some of the drug’s documented side effects.


Q: What should be done if the Rapamune solution accidentally gets spilled on the skin?

Product handling guidelines state that if Rapamune solution accidentally contacts the skin or eyes, the affected area is to be washed immediately and thoroughly using soap and water.


Q: Can Rapamune cause complications like protein in the urine?

Official regulatory warnings indicate that the use of Rapamune has been associated with the occurrence of protein in the urine, a condition known as proteinuria. This is part of the established safety profile.


Q: Does Rapamune have a known effect on blood sugar levels or risk of diabetes?

Official regulatory documents list high blood sugar (hyperglycemia) and the development of diabetes mellitus as documented adverse reactions. This indicates a known effect on the body's metabolic function.


Q: Is it common for patients to require other medicines to manage the side effects of Rapamune?

Studies and official information indicate a high frequency of elevated cholesterol and triglyceride levels. Regulatory labeling notes that additional lipid-lowering therapy may be necessary to manage these specific metabolic changes.


Q: Is hair loss a reported side effect of Rapamune?

Hair loss, medically known as alopecia, has been reported in clinical experience and is listed in the official adverse events documentation for Rapamune.


Q: Are there specific viral infections that can reactivate while taking Rapamune?

Official safety warnings describe that the immunosuppressive nature of Rapamune can lead to the activation of latent viral infections. Specific examples mentioned in regulatory information include BK virus infection and Progressive Multifocal Leukoencephalopathy (PML).


Q: Does the taste of the Rapamune oral solution commonly cause issues for patients?

The official preparation guidelines for the oral solution advise mixing the medication only with water or orange juice, but not with other liquids. This instruction, provided in regulatory labeling, is generally intended to help make the oral administration of the solution easier to manage for patients.


Q: What is the recommendation for breastfeeding while taking Rapamune?

Official regulatory information indicates it is unknown whether Rapamune is excreted into human milk. The regulatory documents state that a decision must be made, in consultation with a healthcare provider, to discontinue either nursing or the drug, considering the importance of the medication to the mother.

How should Rapamune be stored and disposed of?

How to Store and Dispose of Rapamune (Sirolimus)

Storage requirements for Rapamune differ by formulation and must be strictly followed to ensure product stability.

  • Rapamune Tablets: Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Tablets require a tight, light-resistant, and child-resistant container.
  • Rapamune Oral Solution: This form must be stored refrigerated at 2 C to 8 C (36 F to 46 F) and must not be frozen.
Handling and Stability Requirement
Light Protection Both forms must be protected from light.
Post-Opening Shelf-Life Use the oral solution within one month after opening.
Prepared Dose Stability A measured dose in a syringe must be used within 24 hours.

All Rapamune products must be kept out of the sight and reach of children.

For disposal, the medicine must not be thrown into wastewater or household waste; consult a healthcare professional or pharmacist for specific instructions on discarding unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rapamune found in:

A-Z Index: